Being tested
FcRn / IgG reduction, IVIG, plasma exchange: slow disability worsening in NMOSD
NMOSD · FcRn / IgG reduction, IVIG, plasma exchange
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 2
- Running now
- 2
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 2
These linked trials do not set the status.
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Being tested
Related hypotheses
- FcRn / IgG reduction, IVIG, plasma exchange: slow disability worsening in early MS (CIS or RIS)
- FcRn / IgG reduction, IVIG, plasma exchange: slow disability worsening in MS (type not specified)
- Efgartigimod alfa: slow disability worsening in NMOSD
- Human immunoglobulin g: slow disability worsening in NMOSD
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error